search
Back to results

Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis (Endoth-FPI)

Primary Purpose

Pulmonary Fibrosis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
endothelial function
Sponsored by
Hopital Foch
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Pulmonary Fibrosis focused on measuring endothelial function, idiopathic pulmonary fibrosis

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • IPF according to ATS/ERS 2011's criteria
  • Stable IPF (no reduction of FVC or DLCO of more than 10% and 15% respectively)

Exclusion Criteria:

  • Patients with a significant disease other than IPF. A significant disease is defined as a disease which, in the opinion of the investigator, may influence the results of the trial.
  • Pregnant or nursing women.
  • Non-pulmonary fibrosis
  • treatment by pulmonary vasodilators that cannot be stopped for 24 hours for the assessment of endothelial function

Sites / Locations

  • Hopital Europeen Georges Pompidou, dpt of pneumology
  • Hopital Foch

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pulmonary idiopathic fibrosis

Arm Description

Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria

Outcomes

Primary Outcome Measures

measure of reactive hyperemia-peripheral artery tone index

Secondary Outcome Measures

endothelial function
measure of reactive hyperemia-peripheral artery tone index
measure of reactive hyperemia-peripheral artery tone index
measure of reactive hyperemia-peripheral artery tone index at IPF exacerbation or PAHT's occurence

Full Information

First Posted
October 29, 2015
Last Updated
March 16, 2021
Sponsor
Hopital Foch
search

1. Study Identification

Unique Protocol Identification Number
NCT02594059
Brief Title
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
Acronym
Endoth-FPI
Official Title
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
December 19, 2012 (Actual)
Primary Completion Date
July 15, 2020 (Actual)
Study Completion Date
July 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hopital Foch

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to assess the peripheral endothelial function in adult patients with idiopathic pulmonary fibrosis (IPF) and the relationship between the peripheral endothelial function and the severity of the IPF.
Detailed Description
The primary criteria is the peripheral endothelial function that will be assessed by the measure of flow-mediated dilation (reactive hyperemia-peripheral artery tone index). The pulmonary function will be assessed by the measures of the forced expiratory volume at one second (FEV1), the forced vital capacity (FVC) and the total lung capacity (TLC) and the diffusing capacity of the lung for carbon monoxide (DLCO). The dyspnea will be assessed with the New York Heart Association (NYHA) score. The exercise capacity will be assessed by the 6-min walk test. Pulmonary arterial pressure will be recorded through cardiac echography or catheterization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Fibrosis
Keywords
endothelial function, idiopathic pulmonary fibrosis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pulmonary idiopathic fibrosis
Arm Type
Experimental
Arm Description
Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
Intervention Type
Other
Intervention Name(s)
endothelial function
Intervention Description
measure of reactive hyperemia-peripheral artery tone index
Primary Outcome Measure Information:
Title
measure of reactive hyperemia-peripheral artery tone index
Time Frame
day 1
Secondary Outcome Measure Information:
Title
endothelial function
Description
measure of reactive hyperemia-peripheral artery tone index
Time Frame
1, 2 and 3 years
Title
measure of reactive hyperemia-peripheral artery tone index
Description
measure of reactive hyperemia-peripheral artery tone index at IPF exacerbation or PAHT's occurence
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: IPF according to ATS/ERS 2011's criteria Stable IPF (no reduction of FVC or DLCO of more than 10% and 15% respectively) Exclusion Criteria: Patients with a significant disease other than IPF. A significant disease is defined as a disease which, in the opinion of the investigator, may influence the results of the trial. Pregnant or nursing women. Non-pulmonary fibrosis treatment by pulmonary vasodilators that cannot be stopped for 24 hours for the assessment of endothelial function
Facility Information:
Facility Name
Hopital Europeen Georges Pompidou, dpt of pneumology
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Hopital Foch
City
Suresnes
ZIP/Postal Code
92150
Country
France

12. IPD Sharing Statement

Learn more about this trial

Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis

We'll reach out to this number within 24 hrs